Up-regulation of microRNA-497-5p inhibits colorectal cancer cell proliferation and invasion via targeting PTPN3. 2019

Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Changchun 130021, Jilin, China.

To investigate the role of microRNA-497-5p (miR-497-5p) in the tumorigenesis of colorectal cancer (CRC), the present study applied qRT-PCR to detect the expression level of miR-497-5p in both clinical samples and CRC cell lines. Furthermore, to specifically evaluate the carcinogenic role of miR-497-5p in CRC, the expression of miR-497-5p was monitored by transfecting with the mimics or inhibitors of miR-497-5p. Transwell assay as well as CCK-8 assay were used to determine the functions of miR-497-5p on cell invasion, migration and proliferation, respectively. miR-497-5p expression was remarkably down-regulated in clinical samples with cancer development as well as in CRC cell lines. Additionally, low miR-497-5p expression was remarkably correlated with higher TNM stage and lymph node metastasis of CRC patients. Up-regulation of miR-497-5p significantly inhibited proliferation, migration, and invasion of LOVO CRC cell line. Conversely, antagonizing miR-497-5p significantly promoted cell proliferation, migration and invasion. Mechanistic analysis revealed that miR-497-5p directly bound to its downstream target, protein tyrosine phosphatase non-receptor type 3 (PTPN3), whose aberrant expression partially reversed inhibition of cell proliferation and migration. Taken together, the present study elucidated the inhibitory role of miR-497-5p in CRC via targeting PTPN3, which potentiated miR-497-5p as a potential therapeutic target for combating CRC.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
August 2020, Bioscience reports,
Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
June 2020, Bioscience reports,
Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
February 2023, World journal of gastrointestinal oncology,
Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
March 2019, Oncology letters,
Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
September 2016, Oncotarget,
Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
August 2021, Experimental and therapeutic medicine,
Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
April 2021, Experimental and therapeutic medicine,
Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
September 2019, Bioscience reports,
Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
September 2016, DNA and cell biology,
Sen Hong, and Zhenkun Yan, and Helei Wang, and Lei Ding, and Miaomiao Bi
January 2016, OncoTargets and therapy,
Copied contents to your clipboard!